The plasmid constructs producing shRNA corresponding to the conserved 3D polymerase of Foot and Mouth Disease virus protects guinea pigs against challenge virus

2008 ◽  
Vol 33 (3) ◽  
pp. 263-271 ◽  
Author(s):  
Dechamma Hosur Joyappa ◽  
Sarika Sasi ◽  
Kumar C. Ashok ◽  
Golla Rama Reddy ◽  
Veluvarthy V. S. Suryanarayana
Keyword(s):  
Disease Virus ◽  
Guinea Pigs ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Challenge Virus ◽  
Mouth Disease Virus ◽  
Foot And Mouth

scholarly journals A Vaccine Based on the A/ASIA/G-VII Lineage of Foot-and-Mouth Disease Virus Offers Low Levels of Protection against Circulating Viruses from the A/ASIA/Iran-05 lineage

Viruses ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 97
Author(s):  
Nagendrakumar Balasubramanian Singanallur ◽  
Phaedra Lydia Eblé ◽  
Anna Barbara Ludi ◽  
Bob Statham ◽  
Abdelghani Bin-Tarif ◽  
...  
Keyword(s):  
Disease Virus ◽  
Vaccine Strain ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Potency Ratio ◽  
Challenge Virus ◽  
Mouth Disease Virus ◽  
Recent Emergence ◽  
Foot And Mouth ◽  
The Cross

The recent emergence and circulation of the A/ASIA/G-VII (A/G-VII) lineage of foot-and-mouth disease virus (FMDV) in the Middle East has resulted in the development of homologous vaccines to ensure susceptible animals are sufficiently protected against clinical disease. However, a second serotype A lineage called A/ASIA/Iran-05 (A/IRN/05) continues to circulate in the region and it is therefore imperative to ensure vaccine strains used will protect against both lineages. In addition, for FMDV vaccine banks that usually hold a limited number of strains, it is necessary to include strains with a broad antigenic coverage. To assess the cross protective ability of an A/G-VII emergency vaccine (formulated at 43 (95% CI 8–230) PD50/dose as determined during homologous challenge), we performed a heterologous potency test according to the European Pharmacopoeia design using a field isolate from the A/IRN/05 lineage as the challenge virus. The estimated heterologous potency in this study was 2.0 (95% CI 0.4–6.0) PD50/dose, which is below the minimum potency recommended by the World Organisation for Animal Health (OIE). Furthermore, the cross-reactive antibody titres against the heterologous challenge virus were poor (≤log10 0.9), even in those cattle that had received the full dose of vaccine. The geometric mean r1-value was 0.2 (95% CI 0.03–0.8), similar to the potency ratio of 0.04 (95% CI 0.004–0.3). Vaccination decreased viraemia and virus excretion compared to the unvaccinated controls. Our results indicate that this A/G-VII vaccine does not provide sufficient protection against viruses belonging to the A/IRN/05 lineage and therefore the A/G-VII vaccine strain cannot replace the A/IRN/05 vaccine strain but could be considered an additional strain for use in vaccines and antigen banks.

Development of Protective Immunity against Inactivated Iranian Isolate of Foot-and-Mouth Disease Virus Type O/IRN/2007 Using Gamma Ray-Irradiated Vaccine on BALB/c Mice and Guinea Pigs

Intervirology ◽  
2015 ◽  
Vol 58 (3) ◽  
pp. 190-196 ◽  
Author(s):  
Farahnaz Motamedi-Sedeh ◽  
Hoorieh Soleimanjahi ◽  
Amir Reza Jalilian ◽  
Homayoon Mahravani ◽  
Kamalodin Shafaee ◽  
...  
Keyword(s):  
Immune Responses ◽  
Disease Virus ◽  
Guinea Pigs ◽  
Gamma Ray ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Economic Losses ◽  
Mouth Disease Virus ◽  
Foot And Mouth ◽  
Fmdv Type

Objectives: Foot-and-mouth disease virus (FMDV) causes a highly contagious disease in cloven-hoofed animals and is the most damaging disease of livestock worldwide, leading to great economic losses. The aim of this research was the inactivation of FMDV type O/IRN/1/2007 to produce a gamma ray-irradiated (GRI) vaccine in order to immunize mice and guinea pigs. Methods: In this research, the Iranian isolated FMDV type O/IRN/1/2007 was irradiated by gamma ray to prepare an inactivated whole virus antigen and formulated as a GRI vaccine with unaltered antigenic characteristics. Immune responses against this vaccine were evaluated on mice and guinea pigs. Results: The comparison of the immune responses between the GRI vaccine and conventional vaccine did not show any significant difference in neutralizing antibody titer, memory spleen T lymphocytes or IFN-γ, IL-4, IL-2 and IL-10 concentrations (p > 0.05). In contrast, there were significant differences in all of the evaluated immune factors between the two vaccinated groups of mice and negative control mice (p < 0.05). The protective dose 50 for the conventional and GRI vaccines obtained were 6.28 and 7.07, respectively, which indicated the high potency of both vaccines. Conclusion: GRI vaccine is suitable for both routine vaccination and control of FMDV in emergency outbreaks.

scholarly journals Intranasal Immunization of Guinea Pigs with an Immunodominant Foot-and-Mouth Disease Virus Peptide Conjugate Induces Mucosal and Humoral Antibodies and Protection against Challenge

2003 ◽  
Vol 77 (13) ◽  
pp. 7486-7491 ◽  
Author(s):  
D. Fischer ◽  
D. Rood ◽  
R. W. Barrette ◽  
A. Zuwallack ◽  
E. Kramer ◽  
...  
Keyword(s):  
Disease Virus ◽  
Guinea Pigs ◽  
Neutralizing Antibodies ◽  
Immunoglobulin A ◽  
Foot And Mouth Disease ◽  
Keyhole Limpet Hemocyanin ◽  
Mouth Disease ◽  
Mouth Disease Virus ◽  
Foot And Mouth ◽  
Nasal Secretions

ABSTRACT Guinea pigs immunized intranasally with a keyhole limpet hemocyanin-linked peptide, corresponding to the prominent G-H loop of the VP1 protein of foot-and-mouth disease virus, raised substantial levels of antipeptide and virus-neutralizing antibodies in sera and of peptide-specific secretory immunoglobulin A in nasal secretions. In groups of animals immunized intranasally without adjuvant, 86 percent were fully protected upon challenge with homotypic virus. Surprisingly, animals given the peptide conjugates plus the mucosal adjuvant cholera toxin were afforded only partial protection in that primary lesions were observed in most animals, although spread to other feet was prevented. These results indicate that intranasal inoculation with the peptide offers a potential route of vaccination against foot-and-mouth disease and may be useful for eliciting protection in the upper respiratory tracts of susceptible animals.

Sign in / Sign up

Export Citation Format

Share Document